Jupiter Endovascular Exits Stealth Mode, Raises Financing for Pivotal Trial

August 15, 2024—Jupiter Endovascular, Inc., a medical technology start-up, announced that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round, which included participation from multiple strategic investors.

The company also announced the appointment of Carl J. St. Bernard as Jupiter Endovascular’s CEO. St. Bernard joins Jupiter from Alta Biomaterials, where he was President and CEO.

According to the press release, Jupiter Endovascular is developing a new class of endovascular procedures using its Endoportal Control technology to bring the precision and control of direct surgical access to catheter-based interventions. The funding will be used to support an upcoming pivotal trial for pulmonary embolism and development of additional clinical applications of the Endoportal Control technology.

Jupiter Endovascular stated that St. Bernard has more than 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also a board director at AdvaMed.

“I am very excited to join the Jupiter Endovascular team,” commented St. Bernard in the press release. “The Endoportal Control technology, which leverages Jupiter’s unique and exclusive intellectual property to create a catheter-based device that flexibly navigates through a patient’s vasculature before fixing into a stable position, is designed to give interventionalists the confidence and support they need to deliver a prescribed cardiovascular therapy. This represents a generational advance in technology with the potential to revolutionize the treatment of millions of patients worldwide.”

St. Bernard continued, “We are thrilled to partner with Sonder Capital and our other highly valued investors as we bring this innovation to the clinic and create the foundation for our entry into the pulmonary embolism market and future clinical areas where we see a compelling opportunity for Endoportal Control to improve the lives and well-being of patients.”